Navigation Links
EntreMed's Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Date:4/14/2008

New Drugs on the Horizon Session Highlights New Small Molecule Drug

Candidates

ROCKVILLE, Md., April 14 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical and mechanism of action data for its selective kinase inhibitor, ENMD-2076. On Sunday, April 13, 2008, Mark R. Bray, Ph.D., Vice President, Research, gave an oral presentation during the "New Drugs on the Horizon 2" symposium at the American Association for Cancer Research (AACR) Annual Meeting being held this week in San Diego, California.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

During the presentation, Dr. Bray highlighted ENMD-2076's unique combination of antiangiogenic, cell cycle, and antiproliferative activities. In preclinical studies, ENMD-2076 demonstrated potent activity against Aurora A and tyrosine kinases linked to promoting cancer and inflammatory diseases. ENMD-2076 acts through multiple pathways resulting in antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial, dose-dependent efficacy as a single agent in multiple xenograft models, including tumor regression in breast, colon, and leukemia models. ENMD-2076 is an orally active, multi-kinase inhibitor that has shown an acceptable toxicity profile in multiple preclinical studies without cardiovascular effects.

Dr. Bray commented on the presentation, "We are fortunate to have been selected to showcase the potent activity of ENMD-2076 during t
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
3. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
4. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
5. Study Shows Coronado Biosciences Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models
6. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
7. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
10. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
11. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are currently living ... will die with Alzheimer’s or another dementia, according to ... many Americans into looking for ways to improve their ... cognitive disorders. Jonathan Weisman, president of Biohack Pure, is ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Histogen, Inc., ... products of cells grown under simulated embryonic conditions, today ... agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products ... , This agreement is an amendment to the ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... ... Earned Value Management can improve control over clinical development costs, payments, and accruals and ... , ... June 11, 2009 -- ClearTrial ( www.cleartrial.com ), a leading provider of clinical trial ...
... STAAR Surgical Company (Nasdaq: STAA ), a ... products, today announced that the FDA has granted 510(k) ... the Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone ... a new era of insertion devices for the company ...
... June 11 New data from Phase 3 ... (NYSE: WYE ) investigational pneumococcal vaccine, Prevenar 13* ... provide coverage against the 13 most prevalent serotypes associated with ... children younger than five worldwide. , , ...
Cached Biology Technology:ClearTrial Industry Expert to Lead Session at DIA Annual Meeting on Improving Accrual and Contract Management in Clinical Trials 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6
(Date:7/10/2014)... 10, 2014) Consuming a whole fresh avocado with ... enhanced provitamin A carotenoid (alpha- and beta-carotene) absorption and ... vitamin A, according to new research (1) published ... , Vitamin A is involved in reproductive health ... and vision; and has antioxidant properties. Provitamin A carotenoids, ...
(Date:7/9/2014)... diseases can occur simultaneously in distinct sites in ... effective for one disorder may exacerbate the other. ... which alleviates joint disease but can worsen periodontal ... of The American Journal of Pathology ... anti-arthritic drugs, specifically DTrp8-ɣMSH (DTrp), that acts via ...
(Date:7/9/2014)... one gene for another in a line of living ... reality within this decade. As with any new technology, ... disease-causing genes in humans, for example--as well as questions ... of those concerns to rest: using gene-editing techniques on ... in the cells. The new results were published July ...
Breaking Biology News(10 mins):New research: Fresh avocado enhances absorption of essential nutrients for healthy living 2New class of anti-arthritis drugs effectively treats multiple inflammatory diseases 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3
... Rebekah E. Gee MD MPH FACOG, Assistant Professor, LSU ... and Medicine, has been chosen to receive a Recognition ... Leadership Award from the Association of Maternal & Child ... vision, and contributions to the health of women, children, ...
... The University of Michigan,s first human embryonic stem cell line ... registry, making the cells available for federally-funded research. It is ... University of Michigan to be placed on the registry. ... derived in October 2010 from a cluster of about 30 ...
... cues from their rivals the honeybees to learn where the ... Mary, University of London. Writing in the journal ... Biological and Chemical Sciences explain how they trained a colony ... by a different species, the honeybee ( Apis mellifera ), ...
Cached Biology News:LSUHSC's Gee honored for improving health of women, children and families 2U-M human embryonic stem cell line placed on national registry 2U-M human embryonic stem cell line placed on national registry 3Bumblebees get by with a little help from their honeybee rivals 2
...
...
... Ribonuclease III (RNase III) from E. ... double-stranded RNA (dsRNA) to dsRNA fragments that ... dsRNA results in dsRNA fragments of 12-15 ... RNA composed of canonical ribonucleotides as well ...
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
Biology Products: